<DOC>
	<DOCNO>NCT00137423</DOCNO>
	<brief_summary>To evaluate anti-tumor activity SU011248 ( sunitinib ) cytokine-refractory metastatic renal cell carcinoma ( RCC ) administer continuous treatment regimen</brief_summary>
	<brief_title>Study Of SU011248 ( Sunitinib ) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven renal cell carcinoma metastasis . Evidence unidimensionally measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . Failure 1 prior cytokinebased therapy metastatic disease . Patients treat IFNá alone must receive IFNá least 4 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Resolution acute toxic effect prior therapy surgical procedure grade 1 . Adequate organ function Prior treatment systemic therapy 1 cytokinebased therapy . Previous treatment SU011248 ( sunitinib ) clinical trial . Major surgery , radiation therapy , systemic therapy within 4 week start study treatment . Diagnosis second malignancy within last 3 year , except basal cell carcinoma , squamous cell skin cancer , situ carcinoma adequately treat evidence recurrent disease 12 month . History known brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease screen Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan . Any follow within 12 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias grade 2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . Hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) . Ongoing treatment therapeutic dos Coumadin ( however , low dose Coumadin 2 mg PO daily deep vein thrombosis prophylaxis allow ) . Known human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>